
|Articles|October 8, 2012
FDA gives green light to ANDA for chewable diabetes tablet
FDA has approved Boston Therapeutic’s petition to file an Abbreviated New Drug Application (ANDA) for a new, chewable tablet formulation of the diabetes drug metformin hydrochloride. The company plans to market the new formulation under the name Pazamet.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
The Prodigious PBM Pivot: How Supply Chain Entities Will Move Forward After CAA 2026
2
Q&A: Pharmacists Can Address ADA Standards Across All Settings
3
Executive Order Calls for Realignment of Childhood Vaccines
4
Embedded Pharmacists Are Vital Yet Underutilized in Diabetes Care
5





























































